Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

14 results about "Hemopressin" patented technology

Hemopressin (Hp) is an alpha hemoglobin fragment with the sequence PVNFKFLSH, originally identified in extracts of rat brain using an enzyme capture technique. It binds cannabinoid receptors, acting as an inverse agonist at CB₁ receptors. Longer forms of hemopressin containing 2-3 additional amino acids on the N-terminus have been identified in extracts of mouse brain. These longer hemopressin peptides, named RVD-Hpα and VD-Hpα, bind to CB1 receptors and were originally reported to be agonists. In addition to the Hp peptides from alpha hemoglobin, a related peptide from beta hemoglobin has been found in mouse brain extracts; this peptide, named VD-Hpβ, is also an agonist at CB1 cannabinoid receptors. Hemopressin is not an endogenous peptide but rather an extraction artefact [Bauer M, Chicca A, Tamborrini M, Eisen D, Lerner R, Lutz B, Poetz O, Pluschke G, Gertsch J. Identification and quantification of a new family of peptide endocannabinoids (Pepcans) showing negative allosteric modulation at CB1 receptors. J Biol Chem. 2012 Oct 26;287(44):36944-67. doi: 10.1074/jbc.M112.382481. Epub 2012 Sep 5.]. The only endogenous peptide found endogenously at physiological conditions is RVD-hemopressin (pepcan-12), which has more recently been shown to be a negative allosteric modulator of CB1 receptors and positive allosteric modulator of CB2 receptors [Bauer M, Chicca A, Tamborrini M, Eisen D, Lerner R, Lutz B, Poetz O, Pluschke G, Gertsch J. Identification and quantification of a new family of peptide endocannabinoids (Pepcans) showing negative allosteric modulation at CB1 receptors. J Biol Chem. 2012 Oct 26;287(44):36944-67. doi: 10.1074/jbc.M112.382481. Epub 2012 Sep 5.] [Petrucci V, Chicca A, Glasmacher S, Paloczi J, Cao Z, Pacher P, Gertsch J. Pepcan-12 (RVD-hemopressin) is a CB2 receptor positive allosteric modulator constitutively secreted by adrenals and in liver upon tissue damage. Sci Rep. 2017 Aug 25;7(1):9560. doi: 10.1038/s41598-017-09808-8.]. RVD-hemopressin (pepcan-12) is generated from a pro-peptide called pepcan-23 and these peptides are exclusively found in noradrenergic neurons in the brain and in the adrenal medulla [Hofer SC, Ralvenius WT, Gachet MS, Fritschy JM, Zeilhofer HU, Gertsch J. Localization and production of peptide endocannabinoids in the rodent CNS and adrenal medulla. Neuropharmacology. 2015 Nov;98:78-89. doi: 10.1016/j.neuropharm.2015.03.021. Epub 2015 Mar 31.]

New-type benzazepine fused ring derivative

ActiveUS12600729B2Nervous disorderOrganic chemistryDiseaseVasopressin receptor
A benzazepine fused ring derivative as represented by formula (I) or a pharmaceutically acceptable salt thereof, and the use of a compound in the diagnosis, prevention and / or treatment of diseases related to vasopressin receptors.
Owner:SHANGHAI JEMINCARE PHARMACEUTICALS CO LTD

Therapeutic agent for autism spectrum disorder

To provide a more effective medicine for treating ASD.SOLUTION: A therapeutic agent for autism spectrum disorder, comprising an oxytocin receptor agonist as an active ingredient, wherein the therapeutic agent is administered in combination with a vasopressin 1a receptor antagonist. A therapeutic agent for autism spectrum disorder, comprising an oxytocin receptor agonist as an active ingredient, wherein the therapeutic agent is administered in combination with a vasopressin 30IU receptor antagonist. A therapeutic agent for autism spectrum disorder, wherein the oxytocin-receptor agonist is not agonistic to the vasopressin 1a receptor; a pharmaceutical composition for the treatment of autism spectrum disorder, wherein the pharmaceutical composition comprises an oxytocin-receptor agonist and a vasopressin 1a receptor antagonist as active ingredients; a pharmaceutical composition for the treatment of autism spectrum disorder, wherein the oxytocin-receptor agonist is not agonistic to the vasopressin 30IU receptor; and a pharmaceutical composition for the treatment of autism spectrum disorder, wherein the vasopressin-receptor antagonist is SR49059. 1a.SELECTED DRAWING: None
Owner:HAMAMATSU UNIV SCHOOL OF MEDICINE

Preparation and application of probiotics and fermentation products for removing dampness, tonifying blood and relieving dysmenorrhea

The application belongs to the technical field of microorganisms, and provides a Streptococcus salivarius subsp. thermophilus HX-ST36, which has a preservation number of CGMCC NO. 32955. The Streptococcus salivarius subsp. thermophilus provided by the application can ferment Astragalus membranaceus Bunge-Angelica sinensis. In a cold coagulation and blood stasis type primary dysmenorrhea model mouse, the fermentation product thereof can significantly inhibit the writhing response, and can realize the effects of relieving dysmenorrhea and tonifying blood by reducing the levels of prostaglandin PGF2 and vasopressin ADH in uterine tissue and increasing the hemoglobin (HGB) content. The effect of the fermentation product in removing dampness is verified by improving the dampness signs of a crowd. The application further provides a probiotic preparation and a preparation method of a probiotic fermentation product. The preparation method of the probiotic preparation and the probiotic fermentation product is simple and can be produced on a large scale.
Owner:HUNAN NUTRITION TREE BIOTECHNOLOGY CO LTD

Application of arginine vasopressin in treatment of slow transit constipation

The invention discloses application of arginine vasopressin in treatment of slow transit constipation, and relates to the technical field of medicines for treating slow transit constipation. The arginine vasopressin nose drop is found to have a very good treatment effect on slow transit constipation for the first time, and especially for loperamide-induced slow transit constipation, the arginine vasopressin nose drop can effectively promote intestinal tract movement and improve constipation symptoms. The arginine vasopressin is prepared into nose drops, can bypass a blood brain barrier to enter the brain, directly targets downstream nuclei of AVP neurons in a hypothalamic para-ventricular nucleus PVN nuclei, and intervenes treatment in the nerve center, and the effect is better. The discovery of the invention expands a new application for arginine vasopressin drugs, and also provides a new idea for development of constipation drugs.
Owner:WUHAN BAIYINGNUO MEDICAL TECHNOLOGY CO LTD

Vasopressin-2 receptor antagonist peptides and uses thereof

A peptide may include a sequence having 80% or more amino acid identity with the amino acid sequence of SEQ ID NO. 1, i.e., RPSX1CNLPVKPGPCX2GFFSAFYYSQKX3NKCHSFTYGGCAGNANRFSTX4EKCRRTC X5X6, wherein, X1 is the amino acid residue F or G, X2 is any amino acid residue, except a basic amino acid residue, X3 is the amino acid residue T or D, X4 is the amino acid residue I, L, or E, (i) X5 is V and X6 is G or (ii) X5 is G and X6 is V, and the amino acid located at position 39 is A. Such peptides may have various diagnostic and therapeutic uses.
Owner:COMMISSARIAT A LENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES

Benzazepine compounds, processes for their preparation and their medical use

Benzazepine compounds, methods of making and medical uses thereof. In particular, compounds of Formula II-1 or Formula VIII-1 and pharmaceutical compositions containing the same, and medical uses thereof. The benzazepine compounds can be used for treating diseases associated with vasopressin receptors, in particular hypertension, heart disease, etc.
Owner:FUJIAN SHENGDI PHARM CO LTD +3

Esterification impurity of terlipressin and mannitol and application

The invention belongs to the field of biological medicine, and particularly relates to esterified impurities of terlipressin and mannitol and application of the esterified impurities. The alcohol esterification impurity is a terlipressin mannitol esterification compound generated by deamination and esterification reaction of the 8th asparagine of terlipressin and mannitol, the single isotope molecular weight of the alcohol esterification impurity is 1391.5510, and the structural formula of the alcohol esterification impurity is as shown in the formula I. The alcohol esterification impurity is a terlipressin mannitol esterification compound.
Owner:TIANJIN INST FOR DRUG CONTROL

Composition for prevention, amelioration, or treatment of urination-related diseases comprising cephalotocin

ActiveUS12558397B2Peptide/protein ingredientsUrinary disorderDiseaseVasopressin receptor
The present invention relates to a composition for the prevention, amelioration, or treatment of urination-related disases, comprising cephalotocin. The cephalotocin according to the present invention modulates oxytocin receptors and vasopressin receptors, and has the effect of reducing urine volume by promoting water reabsorption in the kidneys. This means that cephalotocin has a significant antidiuretic effect, and thus, the cephalotocin of the present invention can be variously used in the field of prevention, amelioration, or treatment of urinary disorders or urination-related diseases.
Owner:KOREA RES INST OF CHEM TECH +1

Construction method and application of diuretic-resistant cell model

The invention is applicable to the technical field of biomedicine, relates to a construction method and application of a diuretic-resistant cell model, and establishes the diuretic-resistant cell model by using angiotensin II and aldosterone to jointly induce mouse renal manifold M-1 cells. The model is verified by detecting gene and protein expression levels of aquaporin 2, epithelial sodium channel alpha subunit and arginine vasopressin receptor 2. The method is simple to construct and good in repeatability, can truly reflect the pathological characteristics of diuretic resistance, can stably simulate the state of water-sodium retention caused by excessive activation of a renin-angiotensin-aldosterone system, can reproduce the core characteristic of insufficient curative effect of the diuretic, verifies the occurrence effect of the diuretic resistance, and has a good application prospect. And a stable and controllable in-vitro model is provided for researching a molecular mechanism of diuretic resistance and screening prevention and treatment drugs.
Owner:HUNAN UNIV OF CHINESE MEDICINE

System for detecting igg4-related hypophysitis and / or igg4-related disease

PCT designated stageWO2026177170A1DiseaseAntiendomysial antibodies
The present invention relates to a system for detecting IgG4-related hypophysitis and / or IgG4-related disease in a subject at risk of IgG4-related hypophysitis, comprising an anti-Secretogranin-2 (SCG2) antibody, an anti-Vasopressin-neurophysin2-copeptin (AVP) antibody, and / or an anti-Polyubiquitin-B (UBB) antibody.
Owner:FUJITA HEALTH UNIVERSITY